Product Name :
MAGL-IN-1
Description:
MAGL-IN-1 is a potent, selective, reversible and competitive inhibitor of MAGL, with an IC50 of 80 nM. MAGL-IN-1 exhibits anti-proliferative effects against human breast, colorectal, and ovarian cancer cells. MAGL-IN-1 blocks MAGL in cell-based as well as in vivo assays.
CAS:
2324160-91-8
Molecular Weight:
369.43
Formula:
C22H24FNO3
Chemical Name:
4-fluoro-3-{4-[4-(propan-2-yl)benzoyl]piperidine-1-carbonyl}phenol
Smiles :
CC(C)C1C=CC(=CC=1)C(=O)C1CCN(CC1)C(=O)C1=CC(O)=CC=C1F
InChiKey:
WUUBZNFATQKRPH-UHFFFAOYSA-N
InChi :
InChI=1S/C22H24FNO3/c1-14(2)15-3-5-16(6-4-15)21(26)17-9-11-24(12-10-17)22(27)19-13-18(25)7-8-20(19)23/h3-8,13-14,17,25H,9-12H2,1-2H3
Purity:
≥98% (or refer to the Certificate of Analysis)
Shipping Condition:
Shipped under ambient temperature as non-hazardous chemical or refer to Certificate of Analysis
Storage Condition :
Dry, dark and -20 oC for 1 year or refer to the Certificate of Analysis.{{Micrococcal nuclease} web|{Micrococcal nuclease} Technical Information|{Micrococcal nuclease} In Vitro|{Micrococcal nuclease} custom synthesis|{Micrococcal nuclease} Cancer}
Shelf Life:
≥12 months if stored properly.{{Terizidone} site|{Terizidone} Bacterial|{Terizidone} Purity & Documentation|{Terizidone} In Vitro|{Terizidone} manufacturer|{Terizidone} Cancer}
Stock Solution Storage:
0 – 4 oC for 1 month or refer to the Certificate of Analysis.PMID:23443926
Additional information:
MAGL-IN-1 is a potent, selective, reversible and competitive inhibitor of MAGL, with an IC50 of 80 nM. MAGL-IN-1 exhibits anti-proliferative effects against human breast, colorectal, and ovarian cancer cells. MAGL-IN-1 blocks MAGL in cell-based as well as in vivo assays.|Product information|CAS Number: 2324160-91-8|Molecular Weight: 369.43|Formula: C22H24FNO3|Chemical Name: 4-fluoro-3-{4-[4-(propan-2-yl)benzoyl]piperidine-1-carbonyl}phenol|Smiles: CC(C)C1C=CC(=CC=1)C(=O)C1CCN(CC1)C(=O)C1=CC(O)=CC=C1F|InChiKey: WUUBZNFATQKRPH-UHFFFAOYSA-N|InChi: InChI=1S/C22H24FNO3/c1-14(2)15-3-5-16(6-4-15)21(26)17-9-11-24(12-10-17)22(27)19-13-18(25)7-8-20(19)23/h3-8,13-14,17,25H,9-12H2,1-2H3|Technical Data|Appearance: Solid Power|Purity: ≥98% (or refer to the Certificate of Analysis)|Solubility: DMSO : 62.5 mg/mL (169.18 mM; Need ultrasonic).|Shipping Condition: Shipped under ambient temperature as non-hazardous chemical or refer to Certificate of Analysis|Storage Condition: Dry, dark and -20 oC for 1 year or refer to the Certificate of Analysis.|Shelf Life: ≥12 months if stored properly.|Stock Solution Storage: 0 – 4 oC for 1 month or refer to the Certificate of Analysis.|Drug Formulation: To be determined|HS Tariff Code: 382200|How to use|In Vitro:|MAGL-IN-1 (compound 23) (0.02-200 μM; 96 h) produces an appreciable inhibition of cell viability in all the tested cancer cell lines, with IC50s ranging from 7.9 to 57 μM. MAGL-IN-1 (0.125-1 μM; 30 min) competitively binds to MAGL with 4-nitrophenylacetate, with a Ki of 39 nM. MAGL-IN-1 (10 μM; 90 min) does not significantly inhibit CB1, CB2, FAAH, ABHD6 and ABHD12 activity at the concentration of 10 μM. MAGL-IN-1 (1 nM-100 μM; 15 min) inhibits [3H]2-oleoyl glycerol (2-OG) hydrolysis in a concentration dependent manner in U937 cells, with an IC50 of 193 nM. MAGL-IN-1 (0.01-30 μM; 15 min) inhibits 2-OG hydrolysis in a concentration-dependent manner in mouse brain membrane preparations, with an IC50 of 2.1 μM.|In Vivo:|MAGL (compound 23) (50 mg/kg; a single i.p.) increases the 2-AG level in plasma and brain, and does not alter anandamide (AEA), arachidonic acid and prostaglandin levels in plasma and brain of mice.|Products are for research use only. Not for human use.|